KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

West Pharmaceutical Services (WST) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for West Pharmaceutical Services (WST) over the last 17 years, with Q3 2025 value amounting to $137.9 million.

  • West Pharmaceutical Services' Consolidated Net Income rose 439.06% to $137.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $479.2 million, marking a year-over-year decrease of 90.98%. This contributed to the annual value of $478.0 million for FY2024, which is 1697.06% down from last year.
  • West Pharmaceutical Services' Consolidated Net Income amounted to $137.9 million in Q3 2025, which was up 439.06% from $126.8 million recorded in Q2 2025.
  • Over the past 5 years, West Pharmaceutical Services' Consolidated Net Income peaked at $183.0 million during Q2 2022, and registered a low of $86.4 million during Q1 2025.
  • Its 5-year average for Consolidated Net Income is $137.5 million, with a median of $134.3 million in 2023.
  • Its Consolidated Net Income has fluctuated over the past 5 years, first soared by 12075.72% in 2021, then plummeted by 3243.06% in 2022.
  • Over the past 5 years, West Pharmaceutical Services' Consolidated Net Income (Quarter) stood at $147.7 million in 2021, then plummeted by 32.43% to $99.8 million in 2022, then surged by 33.97% to $133.7 million in 2023, then dropped by 4.19% to $128.1 million in 2024, then increased by 7.65% to $137.9 million in 2025.
  • Its last three reported values are $137.9 million in Q3 2025, $126.8 million for Q2 2025, and $86.4 million during Q1 2025.